10/10/2017 | CVLM | Spectrum to swap $69.5 million 2.75% convertibles for stock, cash
|
2/23/2015 | PP | Market Commentary: Salix flat to lower in active trade after merger news; Spectrum sinks on patent ruling
|
2/23/2015 | CV | Market Commentary: Salix flat to lower in active trade after merger news; Spectrum sinks on patent ruling
|
2/23/2015 | CV | Market Commentary: Morning Commentary: Salix trades actively, lower on merger news; Spectrum sinks on patent ruling
|
12/23/2013 | CV | Spectrum greenshoe fully exercised, lifts convertibles to $120 million
|
12/23/2013 | BK | Spectrum Pharmaceuticals terminates credit facility upon issuing notes
|
12/18/2013 | CV | Market Commentary: Midday Commentary: New Spectrum edges up on debut; Ford lower on disappointing outlook
|
12/18/2013 | CV | New Issue: Spectrum Pharmaceuticals prices $100 million five-year convertibles at 2.75%, up 27.5%
|
12/18/2013 | CV | Market Commentary: Convertibles begin to quiet down ahead of holidays; Spectrum edges up; Ford off on outlook
|
12/17/2013 | CV | Market Commentary: New TTM Technologies adds in active trade; SunEdison paper better; Spectrum shares drop
|
12/17/2013 | CV | Market Commentary: Midday Commentary: New TTM Technologies adds in active trade; planned Spectrum shares lower
|
12/16/2013 | CV | Market Commentary: TTM Technology plans new deal; existing TTM bid higher; Spectrum on tap; USEC adds
|
12/16/2013 | CV | Spectrum Pharmaceuticals offers $100 million five-year convertibles at 2.25%-2.75%, up 27.5%-32.5%
|
11/21/2012 | CVHYPF | Spectrum files $250 million shelf covering preferreds, stock and debt
|
9/11/2012 | BK | Spectrum Pharmaceuticals closes on $75 million revolving facility
|
11/25/2009 | CVHY | Spectrum files $250 million shelf covering preferreds, stock and debt
|
9/18/2009 | PP | New Issue: Spectrum Pharmaceuticals arranges $50 million direct offering of units
|
7/1/2009 | PP | New Issue: Spectrum orchestrates $21 million direct offering of common-share units
|
7/1/2009 | PP | Market Commentary: Neostem, Neuralstem wrap offerings; Spectrum to sell units; Freedom4 aims for £83 million deal
|
6/16/2009 | PP | New Issue: Spectrum Pharmaceuticals arranges $10 million direct offering of units
|
6/16/2009 | PP | Market Commentary: Oro Gold plans units; Spectrum to sell units; FuelCell, Mission to issue stock; PA wraps deal
|
5/27/2009 | PP | Market Commentary: Shoreham nixes units placement; Sabretooth aims for C$40.1 million; Churchill wraps stock sale
|
5/27/2009 | PP | New Issue: Spectrum Pharmaceuticals plans $20 million placement of units with Federated Kaufman
|
5/7/2009 | PP | New Issue: Spectrum Pharmaceuticals concludes $1.17 million placement of stock with insiders
|
12/15/2008 | SS | Biotechnology Value Fund reports passive stake of 5.83% in Spectrum Pharmaceuticals
|
4/15/2008 | CVHY | Spectrum files $150 million shelf registration
|
5/4/2007 | PP | New Issue: Spectrum Pharmaceuticals prices $32.09 million direct placement of stock
|
5/4/2007 | PP | Market Commentary: Spectrum prices $32.08 million direct stock offering; Insmed plans $18.23 million stock sale
|
11/3/2006 | BT | Market Commentary: Celgene sells $1 billion of stock; Hollis-Eden up amid Q3 net loss; Spectrum higher following earnings
|
11/3/2006 | BT | Spectrum reports net cash use of $4.4 million in Q3; upcoming milestone payments expected
|
10/18/2006 | BT | Spectrum planning to launch three new products in next 18 months, start two phase 3 trials
|
9/25/2006 | BT | Market Commentary: Acorda skyrockets on trial data; GPC, Pharmion, Spectrum rise; Dendreon steady on rivals' news
|
9/25/2006 | BT | Spectrum, GPC Biotech, Pharmion say satraplatin trial in prostate cancer yields positive results
|
8/2/2006 | BT | Spectrum says highest dose of ozarelix shows benefits in prostate cancer
|
6/8/2006 | BT | Pharmion, GPC Biotech, Spectrum: Monitoring board recommends satraplatin phase 3 trial continue
|
6/6/2006 | BT | GPC Biotech, Pharmion, Spectrum say new satraplatin clinical data shows cancer drug well-tolerated
|
5/8/2006 | BT | Market Commentary: Monogram Biosciences stock jumps on $25 million Pfizer financing; Myogen releases 1Q earnings
|
4/13/2006 | BT | Spectrum data shows Apaziquone exhibits anti-tumor activity in bladder cancer
|
4/13/2006 | BT | Spectrum: data confirms tumor selectivity of SPI-1620 in prostate cancer
|
4/6/2006 | BT | Spectrum's EOquin trial shows antitumor effect in 30 out of 46 patients
|
4/3/2006 | BT | Spectrum data suggests strong connection between satraplatin and Taxotere, Herceptin
|
3/20/2006 | BT | Market Commentary: Boston Life Sciences' stock up as phase 3 trial ends early; BioMarin's stock dips on follow-on stock deal
|
3/20/2006 | BT | Spectrum acquires Targent's oncology drugs, files NDA for osteosarcoma drug
|
3/15/2006 | BT | Spectrum Pharmaceuticals says net loss increases to $18.6 million in 2005
|
3/14/2006 | BT | Spectrum Pharmaceuticals to file IND for EOquin for bladder cancer; phase 3 trial planned
|
3/13/2006 | BT | Spectrum files 13th abbreviated New Drug Application
|
2/24/2006 | BT | Market Commentary: Corautus, Cepheid deals emerge; BioMarin bounces; GCP gains on PIPEs deal; Par pounced on news
|
2/23/2006 | BT | Spectrum, Par form alliance to develop, market generic drugs
|
1/23/2006 | BT | Spectrum, GPC Biotech license cancer drug satraplatin to Pharmion
|
12/15/2005 | BT | Spectrum, GPC Biotech begin rolling NDA for cancer drug satraplatin
|
12/9/2005 | BT | Spectrum begins phase 2 trial of satraplatin plus Taxol for lung cancer
|
12/5/2005 | BT | Spectrum completes phase 3 enrollment for satraplatin anticancer drug
|
11/21/2005 | BT | Spectrum completes enrollment in phase 2 ozarelix study for treatment of enlarged prostate
|
11/18/2005 | BT | Spectrum drug SPI-1620 enhances delivery of paclitaxel to tumors, study finds
|
11/16/2005 | BT | Spectrum, GPC Biotech say studies show satraplatin combination results in therapeutic synergy against cancer
|
11/15/2005 | BT | Spectrum's EOquin/irradiation combo slows tumor growth more than either used alone, study shows
|
9/16/2005 | PP | Market Commentary: Acacia Research to close $10.53 million direct deal; Advanced Cell raises $17.75 million
|
9/15/2005 | PP | Market Commentary: Spectrum Pharma raises $42 million from direct offering; higher biotech stocks may fuel more volume
|
9/15/2005 | BTPP | New Issue: Spectrum Pharmaceuticals raises $42 million from direct placement of shares
|
12/23/2004 | CVHY | Spectrum Pharmaceuticals files $100 million shelf
|
11/12/2004 | PP | Spectrum Pharmaceuticals converts preferred shares to common stock
|